Aprea Therapeutics Q3 net loss $3.0M; cash runway into Q4 2026; clinical updates on APR-1051 and ATRN-119

Aprea Therapeutics, Inc.

2025-Q3 EPS reported -$1.65 vs consensus -$0.35 ▼ miss (-377.8%)

Cash and cash equivalents $13.7M as of Sep 30, 2025; operating loss $3.1M vs $4.1M YoY.
Net loss $3.0M ($0.47 per basic share) on 6.4M weighted avg shares; R&D expenses $1.6M.
APR-1051 Phase 1: 3 of 4 patients at 100mg QD achieved stable disease; dose escalation advanced to 150mg.
ATRN-119: RP2D set at 1,100mg QD; enrollment paused to explore combination studies with radiation.
Cash sufficient into Q4 2026; anticipates value-creating catalysts in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.